COMMUNIQUÉS West-GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
25/03/2026
Novel Combination Regimen Positions Cemsidomide for Use in Earlier Lines of Therapy WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
25/03/2026
Three clinical programs, one core molecule, and a capital-efficient strategy position Artelo Biosciences for sustained growth beyond a single indication BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
25/03/2026
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
25/03/2026
DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free [...]
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
25/03/2026
UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 diabetes, UBT251 [...]
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman
25/03/2026
Annual General Meeting 2026: Tecan proposes the election of three new members of the Board of Directors and a new Chairman Nina Beikert, Gitte Pugholm Aabo and Guillaume Daniellot will be proposed as new members of the [...]
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
25/03/2026
Intended audience: global business, financial and trade media HERNEXEOS® (zongertinib) and JASCAYD® (nerandomilast) launched in H2, 2025 Group net sales increased 7.3%* to EUR 27.8 billion in 2025 R&D investments [...]
Zelluna ASA [ZLNA]: Annual Report 2025
25/03/2026
Oslo, Norway, 25 March 2026 - Zelluna ASA, a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, announces that the Board of [...]
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
25/03/2026
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class [...]
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
24/03/2026
MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris
24/03/2026
Châtillon, France, le 24 mars (22 :30 CET) 2026 DBV Technologies intégrera les indices CAC Mid 60 et SBF 120 à l'issue de la révision annuelle d'Euronext Paris Les modifications sont entrées en vigueur le lundi 23 mars [...]
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
24/03/2026
Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total [...]
BioCardia Reports 2025 Business Highlights and Financial Results
24/03/2026
SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Solana Company to Release Fourth Quarter and Full Year 2025 Operating Results on March 30, 2026
24/03/2026
NEWTOWN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT) (the “Company” or “HSDT”), a publicly listed company that has expanded its business to include a digital asset treasury dedicated to [...]
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
24/03/2026
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Euronext: DBV – ISIN [...]
BioSyent Announces Grant of Restricted Share Units
24/03/2026
MISSISSAUGA, Ontario, March 24, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 44,222 Restricted Share Units “RSUs” to [...]
Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
24/03/2026
NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “ [...]
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
24/03/2026
CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
24/03/2026
Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in late Q4 2026 Reports [...]

Pages